Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MCRB Seres Therapeutics	$16.25 -8.1%	$12.10	$6.53 ▼ $26.40	$142.27M	2.9	98,910 shs	98,341 shs
OKYO OKYO Pharma	$2.29 -5.0%	$2.71	$0.85 ▼ $3.35	$86.13M	-0.09	175,069 shs	233,855 shs
PLX Protalix BioTherapeutics	$1.53 -0.6%	$1.49	$0.89 ▼ $3.10	$121.80M	-0.21	843,859 shs	675,505 shs
RANI Rani Therapeutics	$0.55 -0.8%	$0.53	$0.39 ▼ $3.75	$39.46M	-0.02	1.19 million shs	557,939 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MCRB Seres Therapeutics	+5.99%	+21.75%	+25.73%	+114.68%	+0.53%
OKYO OKYO Pharma	-9.06%	-22.76%	-19.40%	+30.27%	+143.43%
PLX Protalix BioTherapeutics	+4.05%	-4.35%	+6.21%	-10.47%	+58.57%
RANI Rani Therapeutics	+0.69%	+10.76%	+33.25%	-26.07%	-80.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MCRB Seres Therapeutics	3.2905 of 5 stars	2.9	1.0	4.6	3.0	0.8	0.0
OKYO OKYO Pharma	2.4225 of 5 stars	3.5	5.0	0.0	0.6	1.7	0.0
PLX Protalix BioTherapeutics	3.2368 of 5 stars	3.5	2.0	0.0	2.8	1.7	1.9
RANI Rani Therapeutics	3.1018 of 5 stars	3.5	5.0	0.0	1.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MCRB Seres Therapeutics	1.75	Reduce	$73.67	353.33% Upside
OKYO OKYO Pharma	3.00	Buy	$7.00	205.68% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	880.39% Upside
RANI Rani Therapeutics	3.00	Buy	$7.33	1,235.52% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	$1.61 per share	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A
PLX Protalix BioTherapeutics	$61.95M	1.97	$0.09 per share	17.80	$0.47 per share	3.26
RANI Rani Therapeutics	$1.03M	38.31	N/A	N/A	$0.06 per share	9.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	N/A
OKYO OKYO Pharma	-$4.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.07	N/A	4.94	N/A	-21.03%	-30.89%	-11.74%	N/A
RANI Rani Therapeutics	-$30.02M	-$0.91	N/A	N/A	N/A	N/A	-1,258.76%	-97.97%	N/A

Latest RANI, PLX, MCRB, and OKYO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	RANI Rani Therapeutics	-$0.19	-$0.18	+$0.01	-$0.18	N/A	N/A
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MCRB Seres Therapeutics	N/A	1.57	1.57
OKYO OKYO Pharma	N/A	0.40	0.40
PLX Protalix BioTherapeutics	N/A	1.98	1.27
RANI Rani Therapeutics	2.75	0.54	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MCRB Seres Therapeutics	59.34%
OKYO OKYO Pharma	2.97%
PLX Protalix BioTherapeutics	16.53%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
MCRB Seres Therapeutics	4.70%
OKYO OKYO Pharma	40.46%
PLX Protalix BioTherapeutics	6.50%
RANI Rani Therapeutics	45.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MCRB Seres Therapeutics	330	8.76 million	8.34 million	Optionable
OKYO OKYO Pharma	7	37.61 million	22.39 million	Not Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
RANI Rani Therapeutics	110	71.87 million	39.47 million	Optionable

RANI, PLX, MCRB, and OKYO Headlines

Recent News About These Companies

Wall Street Zen Upgrades Rani Therapeutics (NASDAQ:RANI) to Hold

August 18 at 2:33 AM | americanbankingnews.com

Rani Therapeutics Reports Q2 2025 Financial Results

August 13, 2025 | msn.com

RANI: Second Quarter Financial Results

August 12, 2025 | finance.yahoo.com

Rani (RANI) Q2 Net Loss Improves 16%

August 9, 2025 | theglobeandmail.com

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

August 7, 2025 | globenewswire.com

Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance

July 18, 2025 | finance.yahoo.com

Rani Therapeutics Shares Drop Sharply Following $3 Million Direct Offering Announcement

July 15, 2025 | msn.com

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

July 15, 2025 | globenewswire.com

Rani Therapeutics Shares Surge After ENDO 2025 Presentation Announcement

July 14, 2025 | msn.com

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating ...

July 14, 2025 | bakersfield.comB

Rani Therapeutics to Present Preclinical Data on RaniPill® Capsule at ENDO 2025 Conference

July 14, 2025 | quiverquant.comQ

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

July 14, 2025 | globenewswire.com

Genelux Appoints Groen as General Counsel From Rani Therapeutics

July 8, 2025 | news.bloomberglaw.comN

Rani Therapeutics announces annual meeting results

May 30, 2025 | investing.com

Rani Therapeutics strikes deal to issue new warrants

May 21, 2025 | uk.investing.com

RANI: 1Q:25 Financial Results

May 20, 2025 | finance.yahoo.com

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025 | globenewswire.com

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025 | globenewswire.com

Rani Therapeutics Faces Nasdaq Compliance Challenge

May 6, 2025 | tipranks.com

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

April 23, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RANI, PLX, MCRB, and OKYO Company Descriptions

Seres Therapeutics NASDAQ:MCRB

$16.25 -1.44 (-8.14%)

Closing price 04:00 PM Eastern

Extended Trading

$16.93 +0.68 (+4.18%)

As of 05:57 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

OKYO Pharma NASDAQ:OKYO

$2.29 -0.12 (-4.98%)

Closing price 04:00 PM Eastern

Extended Trading

$2.31 +0.02 (+0.87%)

As of 07:04 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Protalix BioTherapeutics NYSE:PLX

$1.53 -0.01 (-0.65%)

Closing price 04:00 PM Eastern

Extended Trading

$1.57 +0.04 (+2.61%)

As of 07:10 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Rani Therapeutics NASDAQ:RANI

$0.55 0.00 (-0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$0.55 0.00 (-0.75%)

As of 06:30 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time